Fig. 1From: Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)OPEN/TORG2040 study design. NSCLC non-small cell lung cancer, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, DEL deletion, QTc corrected QTBack to article page